Episode

Episode 499: APCCC 2026 - Radioligands in Prostate Cancer

Podcast: The Uromigos
Published: May 25, 2026
Duration seconds: 2238
Processing state: not_requested
Canonical source: https://podcasters.spotify.com/pod/show/the-uromigos/episodes/Episode-499-APCCC-2026---Radioligands-in-Prostate-Cancer-e3jsav8
Audio: https://anchor.fm/s/13347ea8/podcast/play/120514984/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-25%2F424852580-44100-2-46a63ba4af103.m4a
JSON: /v1/public/podcasts/the-uromigos-1214845/episodes/episode-499-apccc-2026-radioligands-in-prostate-cancer
Markdown: /podcast/the-uromigos-1214845/episode-499-apccc-2026-radioligands-in-prostate-cancer.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-499-apccc-2026-radioligands-in-prostate-cancer/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-uromigos-1214845/episode-499-apccc-2026-radioligands-in-prostate-cancer.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

This session features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in prostate cancer treatment. Gain a deep understanding of current practices, challenges, and future directions in radiopharmaceuticals.